

Amendments to the Claims

The following Listing of the Claims replaces all previously submitted listings of claims previously submitted in this application.


Listing of the claims:

1-3. (Canceled)

4. (Currently Amended) The method according to claim [[1]]5, further comprising the ~~administration of~~ administering a P-gp inhibitor, or a pharmaceutically acceptable salt thereof.

5. (Currently Amended) A method of treating a subject who has, ~~or in preventing a subject from getting, a disease or condition selected from the group consisting of~~ Alzheimer's disease, ~~for helping prevent or delay the onset of~~ Alzheimer's disease, ~~for treating subjects with mild cognitive impairment (MCI) and preventing or delaying the onset of~~ Alzheimer's disease in those who would progress from MCI to AD, ~~for treating~~ Down's syndrome, ~~for treating humans who have~~ Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch Type, ~~for treating cerebral amyloid angiopathy and preventing its potential consequences, i.e. single and recurrent lobar hemorrhages, for treating other degenerative dementias, including dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, or diffuse Lewy body type of~~ Alzheimer's disease and who is in need of such

treatment ~~which includes administration of~~ comprising administering a therapeutically effective amount of a compound of formula (I)[[,]] ~~or a pharmaceutically acceptable salt thereof~~:



wherein R₁ is

- a) Cbz-Val;
- b) Cbz-Ala;
- c) Cbz; or
- d) Boc;

R₂ is





- a) H;
- b) C₁₋₆ alkyl, alkenyl, or alkynyl; or
- c) cycloalkyl; and





X is


- a) C=O; or
- b) (CH₂)OH;

or a pharmaceutically acceptable salt thereof.

6. (Previously Presented) The method according to claim 5, wherein the compound of formula (I) is selected from the group consisting of:








and pharmaceutically acceptable salts thereof.

7-8. (Canceled)

9. (Withdrawn) A method for inhibiting beta-secretase activity, comprising contacting an effective amount for inhibition of a compound of formula (I):



wherein R₁ is

- a) Cbz-Val;
- b) Cbz-Ala;
- c) Cbz; or
- d) Boc;

R₂ is

- a) H;

b) C₁₋₆ alkyl, alkenyl, or alkynyl; or

c) cycloalkyl; and


X is

a) C=O; or

b) (CH₂)OH.

10. (Canceled)

11. (Withdrawn) A method for inhibiting production of amyloid beta peptide (A beta) in a cell, comprising administering to said cell an effective inhibitory amount of a compound of formula (I):



wherein R₁ is

a) Cbz-Val;

b) Cbz-Ala;

c) Cbz; or

d) Boc;

R₂ is

a) H;

b) C₁₋₆ alkyl, alkenyl, or alkynyl; or

c) cycloalkyl; and

X is

a) C=O; or

b) (CH₂)OH.

12. (Withdrawn) The method of claim 11, wherein the cell is an animal cell.

13. (Withdrawn) The method of claim 12, wherein the animal cell is a mammalian cell.

14. (Withdrawn) The method of claim 13, wherein the mammalian cell is human.

15-19. (Canceled)

20. (Previously Presented) A method of treatment according to claim 5, further comprising administration of one or more therapeutic agents selected from the group consisting of an antioxidant, an anti-inflammatory, a gamma secretase inhibitor, a neurotrophic agent, an acetyl cholinesterase inhibitor, a statin, an A beta peptide, and an anti-A beta peptide.

21-22. (Canceled)